Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.

Cancer biology & therapy - 1 Jan 2015

Niu Mingshan, Chong Yulong, Han Yan, Liu Xuejiao

Abstract excerpt

Colorectal cancer arises via a multistep carcinogenic process and the deregulation of multiple pathways. Thus, the simultaneous targeting of multiple pathways may be a promising therapeutic approach for colorectal treatment. CRM1 is an attractive cancer drug target, because it can regulate multiple pathways and tumor suppressor proteins. In this study, we investigated the anti-tumor activity of a novel reversible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Active Transport, Cell Nucleus
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopentanes

Share to Exportin 1 Protein

Share to G1 Phase Cell Cycle Checkpoints

Share to HT29 Cells

Share to Karyopherins

Share to Tumor Stem Cell Assay

Source

Open in PubMed Open full text

Identifiers

PMID: 25996664
DOI: 10.1080/15384047.2015.1047569
PMCID: PMC4622914

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.PMID 25996664Read ↗

Inhibiting cancer cell hallmark features through nuclear export inhibitionSemantic proximity Read ↗

Small Molecule Inhibitors of CRM1Semantic proximity Read ↗

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathwaysSemantic proximity Read ↗

Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathwaySemantic proximity Read ↗

The past, present, and future of CRM1/XPO1 inhibitorsSemantic proximity Read ↗

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agentsSemantic proximity Read ↗

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cellsSemantic proximity Read ↗

A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.Semantic proximity Read ↗

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agentsSemantic proximity Read ↗

Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.Semantic proximity Read ↗

Mutations of Key Functional Residues in CRM1/XPO1 Differently Alter Its Intranuclear Localization and the Nuclear Export of Endogenous Cargos.Semantic proximity Read ↗

Using a Simple Cellular Assay to Map NES Motifs in Cancer-Related Proteins, Gain Insight into CRM1-Mediated NES Export, and Search for NES-Harboring Micropeptides.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.